TNF inhibitors are already approved and efficacious for treatment of diseases presenting in end stage fibrosis, including UC, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn’s disease, plaque psoriasis, juvenile idiopathic arthritis, and non-radiographic axial spondyloarthritis. The gene discussed is TNF; the disease is Crohn disease.